Evidence map›Paper›PMID 38263435›Full record

ArticleLeukemia2024

The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification.

K Nachtkamp, C Strupp, M Vukelja, A Kasprzak, D Haase, C Ganster, B Hildebrandt, B Betz, A Giagounidis, C Aul and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

K NachtkampDepartment of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Düsseldorf, Germany. Kathrin.Nachtkamp@med.uni-duesseldorf.de.ORCID http://orcid.org/0000-0001-5893-2298
C StruppDepartment of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Düsseldorf, Germany.
M VukeljaDepartment of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Düsseldorf, Germany.
A KasprzakDepartment of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Düsseldorf, Germany.
D HaaseDepartment of Hematology and Medical Oncology, Georg August University, Göttingen, Germany.
C GansterDepartment of Hematology and Medical Oncology, Georg August University, Göttingen, Germany.ORCID http://orcid.org/0000-0002-7566-5985
B HildebrandtInstitute of Human Genetics, Heinrich Heine University, Düsseldorf, Germany.
B BetzInstitute of Human Genetics, Heinrich Heine University, Düsseldorf, Germany.
A GiagounidisDepartment of Hematology, Oncology and Palliative Care, Marien Hospital, Duesseldorf, Germany.
C AulDepartment of Hematology, Oncology and Clinical Immunology, Johannes Hospital, Duisburg, Germany.
S BlumCentre Hospitalier Universitaire Vaudois, Service d'hématologie, Département d'oncologie, and Lausanne University (UNIL), Lausanne, Switzerland.ORCID http://orcid.org/0000-0003-2275-3081
W K HofmannDepartment of Hematology and Oncology, University Hospital, Mannheim, Germany.
M PfeilstöckerMedical Department for Hematology and Oncology, Hanusch Hospital, Vienna, Austria.
P ValentLudwig Boltzmann Institute for Hematology and Oncology, Hanusch Hospital and Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0003-0456-5095
M LübbertDepartment of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany.
M SeidlInstitute of Pathology, Heinrich Heine University, Düsseldorf, Germany.ORCID http://orcid.org/0000-0002-5559-4980
M RudeliusInstitute of Pathology, Heinrich Heine University, Düsseldorf, Germany.
R StauderDepartment of Internal Medicine, Medical University, Innsbruck, Austria.
O KriegerElisabethinen Hospital, Linz, Austria.
K S GötzeDepartment of Medicine III, Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany.
J BobakDepartment of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Düsseldorf, Germany.ORCID http://orcid.org/0009-0002-3022-5860
A KündgenDepartment of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Düsseldorf, Germany.
F SchulzDepartment of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Düsseldorf, Germany.
S DietrichDepartment of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Düsseldorf, Germany.ORCID http://orcid.org/0000-0002-0648-1832
G KobbeDepartment of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Düsseldorf, Germany.
N GattermannDepartment of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Düsseldorf, Germany.
U GermingDepartment of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Düsseldorf, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Myelodysplastic SyndromesNeoplasmsHumansRegistriesWorld Health Organization

Identifiers

PMID38263435
PMCPMC10844089

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.